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Abstract
Background: Although the prevalence of both obstructive sleep apnoea (OSA) and asthma are both increasing,
little is known about the impact of OSA on the natural history of lung function in asthmatic patients.
Methods: A total of 466 patients from our sleep laboratory were retrospectively enrolled. Of them, 77 patients
(16.5%) had asthma with regular follow-up for more than 5 years. Their clinical characteristics, pulmonary
function, emergency room visits, and results of polysomnography results were analysed.
Results: The patients were divided into three groups according to the severity of the apnoea-hypopnea index
(AHI). The decline in FEV1 among asthma patients with severe OSA (AHI > 30/h) was 72.4 ± 61.7 ml/year (N = 34),
as compared to 41.9 ± 45.3 ml/year (N = 33, P = 0.020) in those with mild to moderate OSA (5 < AHI≤ 30) and 24.3 ±
27.5 ml/year (N = 10, P = 0.016) in those without OSA (AHI≤ 5). For those patients with severe OSA, the decline of
FEV1 significantly decreased after continuous positive airway pressure (CPAP) treatment. After multivariate stepwise
linear regression analysis, only AHI was remained independent factor for the decline of FEV1 decline.
Conclusions: Asthmatic patients with OSA had substantially greater declines in FEV1 than those without OSA.
Moreover, CPAP treatment alleviated the decline of FEV1 in asthma patients with severe OSA.
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Background
Although both asthma and obstructive sleep apnoea
(OSA) are common diseases with increasing prevalence,
the impact of OSA on the natural history of pulmonary
function decline has not been well described. Increased
mortality and morbidities in those with declining pul-
monary function have been revealed in previous studies
on asthmatic patients selected from the general popula-
tion [1–3]. These highlight the role of the decline rate in
pulmonary function in asthmatic patients. Factors asso-
ciated with such rapid decline of pulmonary function in-
clude age, sex, smoking, acute exacerbation, obesity, and
hypoxia [4–6]. While obesity is associated with OSA,
hypoxia during sleep is also a cardinal feature of OSA
[7]. As previous reports, both obesity and hypoxia aggra-
vated the decline of pulmonary function, which implies
the role of OSA in pulmonary function decline of asth-
matic patients. In addition, the impact of OSA on asthma
control such as symptoms, peak flow rate, acute exacer-
bation and quality of life are well documented [7–11].
Moreover, acute exacerbation which is related to the
decline of pulmonary function in asthmatic patients
can be reversed by continuous positive airway pressure
(CPAP) [10, 12, 13]. Therefore, we hypothesize that
OSA is an independent factor associated with the decline
in pulmonary function in patients with asthma, and CPAP
treatment prevents the decline by improving nocturnal
hypoxia and frequency of acute exacerbation.
Although previous studies show that CPAP treatment
cannot improve pulmonary function in asthmatic patients
with OSA [10, 12], the impact of OSA on pulmonary
function decline may require long-term longitudinal
follow-up studies. In this study, the aim of this study was
to evaluate the annual pulmonary function decline in asth-
matic patients with OSA in comparison to those without
in a sleep laboratory-based population, and to examine
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the clinical efficacy of CPAP treatment. The analyses were
mainly based on asthmatic patients with more than 5 years




From January to August 2011, asthmatic patients were
retrospectively recruited from the sleep laboratory of
Chang Gung Memorial Hospital, a tertiary hospital in
Taiwan. Patients were excluded if they were not regularly
followed-up more than 5 years. The Chang Gung Medical
Foundation Institutional Review Board (103-1609B) ap-
proved the study and waived the requirement for informed
consent due to the retrospective nature of this study.
Study design
Each patient’s medical records were reviewed to collect
the clinical characteristics and laboratory results. Informa-
tion, including results of pulmonary function, polysomno-
graphy, and emergency department (ER) visits due to
exacerbations of asthma and CPAP compliance, were ana-
lysed. For asthmatic patients with severe OSA, another 2-
year follow-up for pulmonary function test were also col-
lected for further analysis. Pulmonary function such as
FEV1 and FVC were measured by an electronic spirom-
eter, which was calibrated daily using a 1-litre syringe. For
the correct performance of the procedure as standard
requirement, the difference between at least two FEV1
measurements was <5%. In addition, the highest value of
FEV1 was chosen for the analyses.
Definitions
All patients reported a personal history of asthma such
as episodic breathlessness, cough, wheezing, chest tight-
ness, and seasonal variability. Asthma was confirmed by
clinical and functional assessment as defined by the
American Thoracic Society criteria [14]. Airway revers-
ibility was defined as 12% and 200 ml increase in FEV1
or average daily diurnal peak flow variability is more
than 10% [15]. Regular follow-up was defined as a return
to outpatient clinics of at least every 3 months with pul-
monary function test at least every 6 months. Emergency
room visits were considered when patients went to the
ER due to asthma exacerbation. A maximum of one ER
visit every 3 months was counted. From the charts, the
patients reported themselves as current smokers, ex-
smokers, or never-smokers, but both ex-smokers and
never-smokers were defined as non-smokers.
Polysomnography and CPAP titration
Polysomnography (Alice 5, Respironics) was performed
on all patients using standard techniques. Sleep stages
and arousals were scored according to the AASM criteria
[16]. Established criteria were used to score respiratory
events such as hypopnea, obstructive apnoea, central ap-
noea, mixed type apnoea, and Cheyne-Stokes respiration
[17, 18]. Apnoea was defined as oronasal flow cessation
for more than 10 s. Hypopnea was defined as a 50% reduc-
tion in oronasal flow or a 30% reduction, followed by
arousal or more than 3% decrease in SaO2 [17].
Based on the polysomnography results, OSA was de-
fined as an apnoea-hypopnea index (AHI) >5 per hour, of
which ≥80% were obstructive. Mild-to-moderate OSA was
defined as AHI >5 per hour and AHI ≤30 per hour. Severe
OSA was defined as AHI >30 per hour. To determine op-
timal pressure, CPAP titration was performed according
to standard guidelines [19]. Good CPAP compliance was
defined as >4 h per day for >5 days per week.
Statistical analysis
Data were expressed as mean ± SEM (standard error of
the mean). One-way ANOVA was used for comparison
of continuous variables among the three groups, while
the Kruskal-Wallis test was used for non-normal distri-
butions. Categorical variables were compared by χ2 or
Fisher’s exact test. The Pearson product correlation coeffi-
cient was used to examine correlations between variables
and the decline in FEV1. Multivariate stepwise linear re-
gression analysis was used to determine independent fac-
tors affecting the decline in FEV1. Statistical significance
was set at p < 0.05. Analysis conducted using the SPSS
(version 13.0; SPSS; Chicago, IL) statistical software.
Results
Subject characteristics and polysomnography results
There were 466 patients with polysomnography results
from the sleep laboratory, including 77 (16.5%) with
asthma and regular follow-up more than 5 years. Their
baseline demographics and clinical characteristics (Table 1)
revealed that the mean age of asthmatic patients without
OSA, those with mild-to-moderate OSA, and those with
severe OSA was 49.0 years, 60.0 years, and 62.9 years, re-
spectively. The other characteristics were similar among
the three groups, including the percentage of males, and
baseline pulmonary function such as FEV1 and FVC in
the first year. From the results of polysomnography
(Table 2), AHI, ODI, average SaO2, and lowest SaO2, as
well as sleep architecture like slow-wave sleep stage (N3)
and rapid eye movement (REM) stage, were significantly
worse in asthmatic patients with severe OSA.
Annual decline of FEV1 in asthmatic patients with
different OSA severities
The most important finding of the present study was
that the annual decline in FEV1 of asthmatic patients
with severe OSA was significantly accelerated compared
to those of patients with mild-to-moderate OSA and
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Table 1 Patient characteristics
Characteristics No OSA Mild-to-Moderate OSA Severe OSA p value
n = 10 n = 33 n = 34
Age 49.0 ± 13.6 60.0 ± 13.3 62.9 ± 12.7 0.021
Male, n (%) 6 (60) 25 (75.8) 20 (58.8) 0.348
BMI 23.4 ± 4.0 24.8 ± 4.3 29.7 ± 4.7 0.001
Current Smoker, n (%) 2 (20.0) 10 (30.3) 12 (35.3) 0.653
Pulmonary function Test (1st year)
FEV1/FVC 71.9 ± 13.2 73.2 ± 18.9 79.1 ± 13.9 0.078
FEV1, Litre 2.12 ± 0.44 1.75 ± 0.82 1.91 ± 0.80 0.400
FEV1 (% predicted) 68.6 ± 15.9 65.3 ± 24.6 77.1 ± 25.3 0.132
FVC, Litre 2.94 ± 0.42 2.39 ± 0.83 2.41 ± 0.84 0.096
Decline of FEV1/year, (% from baseline) 1.3 ± 1.3 3.1 ± 3.3 4.3 ± 3.4 0.024
Decline of FEV1/year, (% predicted) 0.0 ± 1.1 1.0 ± 1.9 2.3 ± 3.0 0.027
Decline of FEV1/year (mL) 24.3 ± 27.5 41.9 ± 45.3 72.4 ± 61.7 0.046
Decline of FVC/year, (% from baseline) 1.1 ± 3.6 1.4 ± 3.4 2.6 ± 3.6 0.499
Decline of FVC/year, (% predicted) 0.6 ± 3.4 0.8 ± 2.6 1.6 ± 2.9 0.608
Decline of FVC/year, (mL) 32.5 ± 111.1 39.9 ± 84.4 54.9 ± 76.1 0.735
ER visit, n/year 0.11 ± 0.14 0.48 ± 0.63 0.52 ± 0.62 0.256
Medication
Inhaled glucocorticoid 9 (90) 33 (100) 31 (91.2) 0.208
Inhaled long-acting beta-agonist 6 (60) 25 (75.8) 30 (88.2) 0.128
Leukotriene antagonist 1 (10) 10 (30.3) 21 (61.8) 0.003
Data are presented as mean ± SEM, or number (percentage)
Abbreviations: OSA obstructive sleep apnoea, BMI body mass index, FEV1 forced expiratory volume in 1 second, FVC forced volume capacity, ER emergency department
Table 2 Polysomnography results
Characteristics No OSA Mild-Moderate OSA Severe OSA p value
n = 10 n = 33 n = 34
Total sleep time (minutes) 288.2 ± 88.2 268.3 ± 80.7 253.8 ± 74.6 0.207
Sleep efficiency (%) 76.1 ± 22.9 75.8 ± 16.1 72.1 ± 18.0 0.506
AHI event. h−1 2.4 ± 1.5 16.2 ± 6.6 61.4 ± 20.0 0.001
ODI event. h−1 1.7 ± 1.7 14.5 ± 6.1 52.1 ± 22.8 0.001
Average SaO2 (%) 95.0 ± 1.3 93.1 ± 3.0 91.4 ± 3.3 0.001
Lowest SaO2 (%) 88.2 ± 6.0 82.2 ± 5.5 74.7 ± 9.7 0.001
SaO2 < 90% (%) 0 ± 0 9.1 ± 18.2 20.5 ± 25.9 0.001
SaO2 < 80% (%) 0 ± 0 0.2 ± 0.4 3.3 ± 5.2 0.021
Wake % 13.9 ± 8.1 22.4 ± 13.7 22.7 ± 17.8 0.226
N1 % 20.8 ± 11.0 16.5 ± 11.0 22.3 ± 10.7 0.423
N2 % 27.6 ± 11.5 28.8 ± 11.2 34.1 ± 14.1 0.125
N3 % 23.6 ± 8.4 22.1 ± 10.8 13.4 ± 9.8 0.001
REM % 14.1 ± 3.4 10.3 ± 8.5 7.4 ± 5.9 0.013
Data are presented as mean ± SEM, or number (percentage)
Abbreviations: OSA obstructive sleep apnoea, AHI apnoea-hypopnoea index, ODI oxygen desaturation index, SWS slow wave sleep, REM rapid eye movement,
CPAP continuous positive airway pressure
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those of patients without OSA (72.4 ± 61.7 milli-litre vs.
41.9 ± 45.3 milli-litre vs. 24.3 ± 27.5 milli-litre, p = 0.046)
(Fig. 1). In contrast, the annual decline in FVC was not
significantly different among the three groups.
In terms of possible aetiologies responsible for the an-
nual decline of FEV1, % from baseline, univariate ana-
lysis (Tables 3) revealed that age, AHI, ODI, and ER visit
were significantly associated with the annual decline in
FEV1, % predicted (Fig. 2). Although BMI was signifi-
cantly different between the three groups, it was not sig-
nificantly associated with the annual decline in FEV1, %
from baseline. After multivariate stepwise linear analysis,
only AHI remained independent factor associated with
the annual decline in FEV1, % predicted (Table 4).
CPAP treatment alleviated the rapid decline of FEV1 in
asthmatic patients with severe OSA
Thirty-eight percent (13/34) of asthmatic patients with
severe OSA treated with CPAP had good compliance. In
the annual decline in FEV1 before and after CPAP treat-
ment (Fig. 3), after adequate CPAP treatment for the
next 2 years, the annual decline in FEV1 was 41.2 ±
36.1 mL, which was significantly lower than that before
CPAP treatment (69.4 ± 66.4 mL, p = 0.028). The fre-
quency of ER visits were also decreased after CPAP
treatment from 0.35 ± 0.52 per year to 0.35 ± 0.52 per
year but there was just trend (P = 0.058). The average
CPAP pressure was 8.9 ± 4.2 cmH2O and the average
time of CPAP use was 6.4 h per night.
Discussion
The present study demonstrates that asthmatic patients
with obstructive sleep apnoea have a greater decline in
FEV1 over time than those without OSA. Although age,
AHI, ODI, and ER visits are significant factors associated
with a greater decline in FEV1 under univariate analysis,
only AHI is an independent factor in multivariate analysis.
Moreover, CPAP treatment alleviates the accelerated
decline in FEV1 in asthmatic patients with severe OSA,
which further consolidates the role of OSA in the de-
cline in FEV1 among asthmatic patients.
The natural history of FEV1 decline in asthmatic pa-
tients has been reported to be 38–40.9 ml/year [6, 20–22].
Factors associated with the decline in pulmonary function
are age, sex, smoking, acute exacerbation, obesity, and
hypoxia [4–6]. Furthermore, OSA with obesity and hyp-
oxia as central features, significantly contribute to asthma
control and exacerbation. Thus, it is not surprising that
CPAP treatment of up to 2 years for asthmatic patients
with severe OSA is beneficial not only in terms of quality
of life and in alleviating asthma symptoms but also in re-
ducing FEV1 decline.
Frequent symptoms and exacerbations have been re-
ported to be associated with an excess decline in lung
Fig. 1 Decline in FEV1 per year among the three groups. AHI,
apnoea-hypopnoea index; *p < 0.05 compared to AHI <5; +p < 0.05
compared to 5≤ AHI < 30
Table 3 Univariate analysis of variables associated with average
decline of FEV1, % predicted
Parameter beta Standard error 95% CI p value
Age −0.053 0.020 −0.093 to − 0.012 0.011
ESS −0.280 0.085 −0.323 to 0.021 0.084
BMI −0.077 0.056 −0.189 to 0.036 0.178
Current smoke −1.173 0.599 −2.367 to 0.021 0.054
AHI −0.033 0.009 −0.052 to − 0.014 0.001
ODI −0.035 0.010 −0.056 to −0.015 0.001
SaO2 < 90% (%) −0.014 0.015 −0.043 to 0.015 0.347
SaO2 < 80% (%) −0.091 0.094 −0.280 to 0.097 0.336
ICS −0.091 1.646 −4.581 to 1.977 0.432
ER visit, n/year −0.941 0.470 −1.877 to − 0.005 0.049
Abbreviations: ESS epworth sleepiness scores, BMI body mass index, AHI apnoea-
hypopnoea index, ODI oxygen desaturation index, ICS inhaled corticosteroid,
ER emergency department
Fig. 2 Correlation between the apnoea-hypopnoea index (AHI) and
the decline of FEV1 per year, % predicted
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function among asthmatics [23, 24]. Similarly, the results
of present study also reveal that the number of ER visits is
associated the decline in FEV1. For asthma control, the
presence of OSA is associated with more symptoms, exac-
erbations and worse quality of life. Furthermore, CPAP
treatment can alleviate the symptoms, the frequency of
exacerbations and improve the quality of life [9–12].
Therefore, the decline of FEV1 may be alleviated by CPAP
treatment in asthmatic patients with OSA. This is the first
study reporting more exacerbations in asthmatic patients
with OSA than in patients without OSA based on sleep
lab population. In addition, CPAP treatment can reduce
exacerbations in asthmatic patients with OSA. Such
exacerbation is also associated with the decline in pul-
monary function among asthmatic patients with OSA.
Inhaled corticosteroid (ICS) can alleviate the decline
of FEV1 [22]. In addition, asthmatic patients with obesity
are poor response to ICS [25]. The National Heart Lung
and Blood Institute–sponsored Severe Asthma Research
Program (SARP) has identified and characterized a pheno-
type of severe asthma consisting mainly of non-atopic late-
onset older women with the highest body mass index, who
are poor responders to ICS and frequently require oral
corticosteroid use to manage exacerbations (Cluster 3).
[26] Obesity is frequently associated with OSA. Therefore,
asthmatic patients with OSA may also be poor responders
to ICS, leading to accelerate the decline of FEV1. Another
possible reason responsible to FEV1 decline due to obesity
is that obesity may reduce FEV1 and FVC concurrently.
However, this study reveals that the baseline FEV1 is not
significantly different between groups and there is trend in
FVC, which is worse in severe OSA group. Therefore,
obesity did not reduce FEV1 and FVC concurrently in this
study. Furthermore, BMI is not significant associated with
the decline of FEV1 in univariate analysis. Therefore, obes-
ity is not a significant factor associated with the decline of
FEV1 in asthmatic patients with OSA.
The major limitations of the present study include its
retrospective nature, which may lead to bias in patient
selection, and a relatively small sample size that may
lead to spurious associations and conclusions. Pro-
inflammatory profiles of asthma, such as FeNO, sputum
or peripheral eosinophil counts were not entirely mea-
sured in every study subject in this retrospective study.
A long-term, prospective study with a larger scale study
is needed to corroborate these findings, and include the
pro-inflammatory profiles into analysis for the associ-
ation with annual decline in pulmonary function.
Conclusions
In conclusion, in a sample of the sleep-laboratory popu-
lation, asthmatic patients with OSA have a substantially
greater decline in FEV1 in 5-year follow-up compared to
those without OSA. The impact of OSA on the annual
decline in FEV1 is dose dependent. Moreover, CPAP
treatment alleviates the decline in FEV1 among asthmatic
patients with severe OSA.
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